Development of interferon γ-based immunocytokines targeting renal cancer

OncoImmunology

Volumn 2, Issue 7, 2013, Pages

  Chen, Peirong ^a   Balachandran, Siddharth ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

CD70; Immunocytokines; Interferon; Necroptosis; Necrosis; Renal cell carcinoma; RIP1

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BORTEZOMIB; CD70 ANTIGEN; CYTOKINE; ENZYME INHIBITOR; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOCYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NECROSTATIN 1; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RITUXIMAB; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL DEATH; CELL KILLING; CELL LABELING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; KIDNEY CANCER; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN TARGETING;

EID: 84886945255     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24964     Document Type: Article

References (10)

1. Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, et al. The epidemiology of renal cell carcinoma. Eur Urol 2011; 60:615-21; PMID:21741761; http://dx.doi.org/10.1016/j.eururo.2011.06.049
2. Balachandran S, Adams GP. Interferon-?-Induced Necrosis: An Antitumor Biotherapeutic Perspective. J Interferon Cytokine Res 2013; 33:171-80; PMID:23570383; http://dx.doi.org/10.1089/ jir.2012.0087
3. Thapa RJ, Basagoudanavar SH, Nogusa S, Irrinki K, Mallilankaraman K, Slifker MJ, et al. NF-kappaB protects cells from gamma interferon-induced RIP1- dependent necroptosis. Mol Cell Biol 2011; 31:2934- 46; PMID:21576359; http://dx.doi.org/10.1128/ MCB.05445-11
4. Pasche N, Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012; 17:583-90; PMID:22289353; http://dx.doi. org/10.1016/j.drudis.2012.01.007
5. Chen P, Nogusa S, Thapa RJ, Shaller C, Simmons H, Peri S, et al. Anti-CD70 Immunocytokines for Exploitation of Interferon-?-Induced RIP1-Dependent Necrosis in Renal Cell Carcinoma. PLoS One 2013; 8:e61446; PMID:23613854; http://dx.doi. org/10.1371/journal.pone.0061446
6. Boursalian TE, McEarchern JA, Law CL, Grewal IS. Targeting CD70 for human therapeutic use. Adv Exp Med Biol 2009; 647:108-19; PMID:19760069; http:// dx.doi.org/10.1007/978-0-387-89520-8_7
7. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008; 11:164-79; PMID:18818117; http:// dx.doi.org/10.1016/j.drup.2008.08.002
8. Morais C, Gobe G, Johnson DW, Healy H. The emerging role of nuclear factor kappa B in renal cell carcinoma. Int J Biochem Cell Biol 2011; 43:1537- 49; PMID:21854869; http://dx.doi.org/10.1016/j. biocel.2011.08.003
9. Yang CH, Murti A, Pfeffer SR, Basu L, Kim JG, Pfeffer LM. IFNalpha/beta promotes cell survival by activating NF-kappa B. Proc Natl Acad Sci U S A 2000; 97:13631-6; PMID:11095741; http://dx.doi. org/10.1073/pnas.250477397
10. Xuan C, Steward KK, Timmerman JM, Morrison SL. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 2010; 115:2864-71; PMID:20139095; http://dx.doi.org/10.1182/blood- 2009-10-250555